As one of the largest and most comprehensive epilepsy treatment programs in the nation, Children’s Hospital of Philadelphia’s Pediatric Epilepsy Program is an active participant in the annual meeting of the American Epilepsy Society (AES). Several of our physicians also serve in leadership roles within the AES and its various committees.
The AES Annual Meeting offers extensive education on everything epilepsy, from best practices to breakthrough thinking. From Dec. 1 – 5, 2017, many members of CHOP’s Pediatric Epilepsy Program team were in attendance in Washington, D.C., to present on their work in epilepsy management.
Our team members are engaged in basic science research to define epilepsy mechanisms and management approaches; translational research to bring those advances into clinical practice; and clinical research spanning epidemiological studies, drug studies, epilepsy surgery studies, and critical care epilepsy studies.
CHOP experts at AES 2017
Representatives from CHOP presented on a wide variety of topics.
Dennis Dlugos, MD, MSCE:
- Management of Pediatric Focal Epilepsy
- Empiricism in Seizure Therapy Development
Nicholas Abend, MD, MSCE:
- Neonatal Status Epilepticus
- Designing Clinical Research to Optimize EEG-Guided Seizure Management
- Career Pathways in Epilepsy Care and Research
Conny Tran (from Goldberg NeuroLab):
- In Vivo Two-photon Calcium Imaging Shows Cell Type Specific Activity During Seizure Propagation in an Experimental Model of Dravet Syndrome (presented during “Hot Topics from Young Investigators in the Epilepsy Community”)
Mark Fitzgerald, MD, PhD:
- KCNT1-related Epilepsy: The Quinidine Story
Abend NS, Massey S, Fitzgerald MP, Fung F, Atkin NJ, Xiao R, Topjian AA. Interrater variability of EEG interpretation after pediatric cardiac arrest utilizing standardized critical care EEG terminology.
Witzman SM, Massey SL, Kessler SK, Dlugos DJ, Abend NS. Epic for standardized pediatric and neonatal ICU reporting.
Lin N, Welsh SS, Topjian AA, Abend NS. Safety of intravenous lacosamide in critically ill children.
Fitzgerald MP, Massey SL, Fung F, Kessler SK, Abend NS. Seizures and developmental outcomes in neonates with HIE.
Fitzgerald MP, Smith DM, Moller RS, Fiannacca M, McGinnis E, Gunning B, Rubboli G, Syrbe S, Brilstra E, Picard F, Stamberger H, Weckhuysen S, Striano P, Baglietto MG, Verbeek NE, Barolomei F, Lesca G, Maurey H, Nava C, Hirsch E, Baulac S, Ceulemans B, Schoonjans AS, Helbig I, Dlugos D, and Bearden D. Response to treatment in patients with KCNT1-related epilepsy.
Massey S, Clancy R, Digiovine M, Fitzgerald MP, Fung F, Shou H, Farrar J, Abend N. Inter-rater agreement in neonatal electroencephalogram background scoring.
Cilio MR, Kohrman MH, Miller I, Oh DA, Parikh N, Phillips S, Renfroe JB, Roberts C, Sparagana SP, Wheless JW, Dlugos D, for the INS011-14-029 study investigators. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol oral solution in pediatric patients with treatment-resistant seizure disorders.
Hussain SA, Dlugos DJ, Cilio MR, Oh DA, Parikh N, Sankar R. A phase 2 study of pharmaceutical-grade synthetic cannabidiol oral solution for treatment of refractory infantile spasms.
Fried L, Wright C, Kaznicka Z, Nelson A, Foster C, DiGerolamo K, Kane E. A multidisciplinary approach to improving timely discharges of pediatric patients in the EMU.
Tran C, Goldberg EM. In vivo two-photon calcium imaging shows cell type-specific activity during seizure propagation in an experimental model of Dravet syndrome. Poster 1.014.
Boorady T, Martinez A, O’Brien M, Hagopian S, Hardacker S, Minnick J, Melamed S, Dlugos D, Marsh E, Kessler SK. Poster 3.293
Joshi S, Armstrong D, Shellhaas R, Grinspan Z. Infantile Spasms in Trisomy 21.